Literature DB >> 12809159

Frequency-doubling technology perimetry.

Andrew J Anderson1, Chris A Johnson.   

Abstract

The FDT perimeter is a compact and relatively inexpensive perimeter whose transportability, tolerance to refractive errors, and rapid test times (less than 1 minute per eye) make it a suitable candidate for visual field screening. It is a uniform finding that the C-20-1 screening protocol of the FDT perimeter provides good sensitivity and specificity for the detection of moderate and severe losses in glaucoma. Sensitivity can be increased by use of the C-20-5 screening protocol. In addition, the FDT perimeter demonstrates good sensitivity and specificity for detecting the presence of neuro-ophthalmic disorders, though it may have a limited ability to determine whether a field defect is hemianopic. There is only limited evidence that the FDT can appropriately detect retinal disease. Despite some evidence that the current FDT perimeter may be suitable for staging and monitoring the progression of visual field damage, the large targets used in the test make this of limited practicability. The development of a frequency-doubling test with smaller targets spaced over narrower intervals would improve the ability of FDT perimetry to determine the spatial extent of visual field defects.

Entities:  

Mesh:

Year:  2003        PMID: 12809159     DOI: 10.1016/s0896-1549(03)00011-7

Source DB:  PubMed          Journal:  Ophthalmol Clin North Am        ISSN: 0896-1549


  26 in total

1.  Frequency doubling technology perimetry for neuro-ophthalmological diseases.

Authors:  C A Johnson
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

2.  Characteristics of the normative database for the Humphrey matrix perimeter.

Authors:  Andrew John Anderson; Chris A Johnson; Murray Fingeret; John L Keltner; Paul G D Spry; Michael Wall; John S Werner
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-04       Impact factor: 4.799

3.  Interpretation of the Humphrey Matrix 24-2 test in the diagnosis of preperimetric glaucoma.

Authors:  Jin A Choi; Na Young Lee; Chan Kee Park
Journal:  Jpn J Ophthalmol       Date:  2009-01-30       Impact factor: 2.447

4.  Predicting conversion to glaucoma using standard automated perimetry and frequency doubling technology.

Authors:  Genichiro Takahashi; Shaban Demirel; Chris A Johnson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-01-21       Impact factor: 3.117

5.  Skin Intrinsic Fluorescence and Selected Measures of Visual Function and aging in Older Adults.

Authors:  Barbara E K Klein; Kristine E Lee; John D Maynard; Chris A Johnson; Lorraine Danforth; Ronald Klein
Journal:  Ophthalmic Epidemiol       Date:  2019-04-27       Impact factor: 1.648

6.  Frequency doubling technology and standard automated perimetry in detection of glaucoma among glaucoma suspects.

Authors:  Sagarika Patyal; Atul Kotwal; Ajay Banarji; V S Gurunadh
Journal:  Med J Armed Forces India       Date:  2014-10-25

7.  Combining Frequency Doubling Technology Perimetry and Scanning Laser Polarimetry for Glaucoma Detection.

Authors:  Jean-Claude Mwanza; Joshua L Warren; Jessica T Hochberg; Donald L Budenz; Robert T Chang; Pradeep Y Ramulu
Journal:  J Glaucoma       Date:  2015 Oct-Nov       Impact factor: 2.503

Review 8.  Importance of population-based studies in clinical practice.

Authors:  George Ronnie; Ramesh Sathyamangalam Ve; Lokapavani Velumuri; Rashima Asokan; Lingam Vijaya
Journal:  Indian J Ophthalmol       Date:  2011-01       Impact factor: 1.848

9.  Line bisection in Parkinson's disease: investigation of contributions of visual field, retinal vision, and scanning patterns to visuospatial function.

Authors:  Thomas M Laudate; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Behav Neurosci       Date:  2013-01-28       Impact factor: 1.912

10.  Using frequency-doubling perimetry to detect optic neuropathy in patients with Graves' orbitopathy.

Authors:  Mário L R Monteiro; André L F Portes; Frederico C Moura; Dina B W Regensteiner
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.